Evidence and harm reduction
Novel Psychoactive Substances
An evidence-focused section exploring emerging novel psychoactive substances, with emphasis on data limitations and harm reduction.
Novel Psychoactive Substances
This section provides information on emerging novel psychoactive substances (NPS), with a focus on compounds that have appeared in unregulated markets in recent years.
Many of these substances reach consumers with very limited human safety or efficacy data. The content in this section prioritizes transparency about what is and is not known, while emphasizing harm reduction.
Important Context
- A significant number of novel psychoactive substances have little to no controlled human clinical data.
- Product composition in unregulated markets can be inconsistent or mislabeled.
- The absence of robust human safety data does not indicate that these substances are low-risk.
- This section is intended to support informed decision-making and harm reduction, not to encourage use.
Key Articles
- The Rise of Novel Psychoactive Substances in 2026
- Kratom-Derived Semi-Synthetic Opioids: What's Actually Happening
- 7-Hydroxymitragynine vs MGM-15 vs Mitragynine Pseudoindoxyl
- Harm Reduction Considerations for Kratom-Derived Semi-Synthetic Opioids
This section will be updated as new information becomes available.
7-Hydroxymitragynine vs MGM-15 vs Mitragynine Pseudoindoxyl: A Comparison
7-Hydroxymitragynine vs MGM-15 vs Mitragynine Pseudoindoxyl — potency comparison, safety risks, and evidence gaps. MGM-15 has the least human data. Harm-reduction focused.
Harm Reduction Considerations for Kratom-Derived Semi-Synthetic Opioids
Practical harm reduction information for compounds such as 7-hydroxymitragynine, MGM-15, and mitragynine pseudoindoxyl, with emphasis on known risks and significant data limitations.
Kratom-Derived Semi-Synthetic Opioids: What's Actually Happening
An evidence-focused explanation of the shift toward concentrated and semi-synthetic kratom products, including 7-hydroxymitragynine, MGM-15, and mitragynine pseudoindoxyl.
SR-17018: The Biased Mu-Opioid Agonist That Reverses Morphine Tolerance
SR-17018 is an experimental G protein-biased mu-opioid receptor agonist studied for sustained antinociception without tolerance. Full pharmacology review with mechanism, key studies, safety context, and limitations.
The Rise of Novel Psychoactive Substances in 2026: Trends and Evidence Limitations
An evidence-focused overview of emerging novel psychoactive substances in 2026, including key trends, categories, and significant gaps in human safety data.
Editorial reading context
How to read Novel Psychoactive Substances
An evidence-focused section exploring emerging novel psychoactive substances, with emphasis on data limitations and harm reduction. This guide is intended to help readers make sense of evidence, safety, and practical fit without turning supplement research into a one-size-fits-all checklist. Use it alongside the linked herb and compound profiles for deeper mechanism and safety details.
For Novel Psychoactive Substances, focus on whether the evidence matches the exact outcome you care about, whether the dose discussed is realistic, and whether the safety profile fits your medical context. Strong marketing language should carry less weight than human evidence and transparent product quality.
When a page discusses dependence-forming substances, restricted compounds, or high-risk contexts, treat it as harm-reduction education only. It is not a buying guide, dosing instruction, or substitute for professional care.